By IDSE News Staff
The Novovax COVID-19 vaccine (NVX-CoV2373) demonstrated 90.4% efficacy in preventing symptomatic COVID-19 disease, and showed 100% protective efficacy against moderate and severe disease in people at high risk for developing complications.
In people with high risk for complications from COVID-19, the vaccine showed 91.0% efficacy in preventing symptomatic COVID-19 disease.